How to Buy Organon & Co Stock
Organon & Co
Organon & Co is a general drug manufacturer company located in New Jersey, United States, which is part of the Healthcare sector, and is traded under the ticker OGN on the NYSE exchange.
Organon & Co stock last closed at $10.63, down 4.41% from the previous day, and has decreased 40.94% in one year. It has underperformed other stocks in the Drug Manufacturers - General industry by 0.4 percentage points. Organon & Co stock is currently +1.72% from its 52-week low of $10.45, and -53.98% from its 52-week high of $23.10.
As of Apr 21, 2025, there are 257.95M OGN shares outstanding. The market value of OGN is $2.74B. In the past 24 hours, 4.38M OGN shares were traded.
How to Buy Organon & Co Stock
Wondering how to invest in Organon & Co stock? Here's how.
- Choose where to buy Organon & Co stock: You need to choose a stock brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you decide where to buy Organon & Co stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Fund your investment account: Pick your payment method and add your details.
- Evaluate Organon & Co stock: The Organon & Co ticker symbol is OGN. Is Organon & Co stock a good investment? Should you buy shares of OGN? How do OGN's underlying business fundamentals look? Do top analysts think Organon & Co is a good buy? Why has OGN's stock price moved recently? (Hint: Our stock market research tools can help you figure out if OGN is a good stock to buy).
- Make your OGN purchase: Decide if you will purchase OGN shares at the current market price or use a limit order to buy OGN shares at a given price.
- Get the latest scoop on your OGN investment: Create a watchlist to keep tabs on your investment in Organon & Co stock.
Step 1: Choose where to buy Organon & Co stock
You need an online brokerage account to access the NYSE market and buy OGN shares.
Our favorite brokerage: eToro
Based on our experience, eToro is the best place to buy stocks. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global financial markets: From Tech to Real Estate, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro boasts a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've picked the right brokerage, you need to fill out some personal information so you are able to buy OGN today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to create your new trading account.
- Send your info by pressing the "Create Account" button. Get started with eToro today
Step 3: Fund your investment account
Now that you've filled out your info on the best stock investing app, your next step is to transfer the money for your investment:
Watch the walkthrough below if you need help depositing money into your new brokerage account.
Step 4: Evaluate Organon & Co stock
Once you have figured out the best place to buy Organon & Co stock, it's crucial to analyze their stock prior to buying, so you actually understand the risk as well as the upside.
Organon & Co Numbers
Fundamentals of OGN
WallStreetZen was built to help everyday investors do better fundamental analysis.
You can view all of the due diligence checks on OGN's stock page.
Is OGN stock undervalued?
Investors use many financial metrics, analyses, models, and charts to gauge OGN's fair value.
Using relative valuations metrics:
- OGN could be undervalued based on its P/E ratio of 3.16x, relative to Drug Manufacturers - General industry P/E ratio of 51.51x
- OGN may be undervalued based on its P/B ratio of 5.81x, relative to Drug Manufacturers - General industry P/B ratio of 5.94x
- OGN may be undervalued based on its PEG ratio of 0.75x
You can do additional valuation research on OGN's stock here.
A quick look at OGN Financials
Positive Health Checks:
- There are more short-term assets than short-term liabilities on the OGN balance sheet.
Negative Health Checks:
- OGN earnings of $1.33B is not enough to cover its interest payments.
- OGN profit margin has gone down from 16.3% to 13.5% in the past year.
- Total OGN debt is higher than 5 years ago, relative to shareholder equity.
- OGN has a relatively high debt to equity ratio of 26.76.
- OGN's operating cash flow of $939.00M allows it to safely service it's debt of $8.88B.
- There are more long-term liabilities than short-term assets on the OGN balance sheet.
Do Wall Street analysts think it's a good time to buy Organon & Co stock
Out of 2 Equities analysts who give ratings on OGN, the consensus analyst rating on OGN is a Buy
It's important to note that analyst forecasts are not recommendations, nor are they financial advice.
You can dig deeper into what analysts are forecasting on the Organon & Co stock forecast page.
Metrics for Advanced OGN Traders
OGN Revenue
Last year, OGN earnings were $864.00M. Over the last five year, OGN's earnings have grown by -23.34% per year. This was slower than the Drug Manufacturers - General industry average of 0.89%.
Last year, OGN revenue was $6.40B. Over the past 5 year, OGN's revenue has increased by -3.81% per year. This was slower than the Drug Manufacturers - General industry average of 9.15%.
Find out more about OGN's earnings and revenue performance here.
What are OGN insiders up to?
In the last year, insiders at OGN have sold more shares than they have bought.
Kevin Ali, Chief Executive Officer of OGN, was the latest OGN insider to sell. They sold $391,247.64 worth of OGN shares on Mar 31, 2025.
Learn more about who owns OGN shares here.
Does OGN stock generate passive income?
Organon & Co pays a dividend of 5.27%, compared to the Drug Manufacturers - General industry's average dividend yield of 3.51%. If you owned $1,000 of OGN stock, you would have received $52.68 in the past 12 months.
Dig into more data about Organon & Co dividend yield and history here.
OGN Social Trading Data
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Make your OGN purchase
There are two main order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are mostly fine for most investors. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a given price, use a limit order.
Click the Open Trade button and your broker will execute your order.
If you need more info about buying stocks on eToro, click the how to video below:
Step 6: Get the latest scoop on your OGN investment
Now that you own some shares in OGN, you'll want to keep up with your new investment.
Create a watchlist to get notified of the latest news about your OGN stock.
OGN Feed
How to Buy Stock in Organon & Co
To summarize, here are the 6 steps to buy Organon & Co stock:
- Choose where to buy Organon & Co stock
- Create your brokerage account
- Fund your investment account
- Evaluate Organon & Co stock
- Make your OGN purchase
- Get the latest scoop on your OGN investment
If you require a place to buy stocks, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to watch your new investment in Organon & Co, create your watchlist below.
Other Content You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.